Clinical Outcomes and Quality of Life in Older De Novo Kidney Transplant Recipients Under Once‐Daily Tacrolimus Formulations: The BITACORA Study

Fuente: Wiley Open Access
Salvato in:
Dettagli Bibliografici
Autori principali: Amado Andrés, Sara Jiménez, Maria José Aladrén Regidor, Francesc Moreso, Marta Crespo, Nuria Serra Cabañas, Gonzalo Gómez, Verónica López, Maria del Carmen Díaz Corte, Pilar Fraile‐Gómez, Inmaculada Lorenzo, Juan Carlos Ruiz San Millán, Laura Cañas, Alberto Rodríguez Benot, Natividad Calvo Romero, Fritz Diekmann, Alicia Mendiluce, Constantino Fernández Rivera, Roberto Gallego, Carlos Jiménez, Paloma L. Martin‐Moreno, Ernesto Fernández Tagarro, Cándido Díaz, Basilio Martín Urcuyo, Francisco Manuel González Roncero
Natura: Artículo Open Access
Pubblicazione: Wiley 2026
Soggetti:
Accesso online:
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
_version_ 1867008450889777152
author Amado Andrés
Sara Jiménez
Maria José Aladrén Regidor
Francesc Moreso
Marta Crespo
Nuria Serra Cabañas
Gonzalo Gómez
Verónica López
Maria del Carmen Díaz Corte
Pilar Fraile‐Gómez
Inmaculada Lorenzo
Juan Carlos Ruiz San Millán
Laura Cañas
Alberto Rodríguez Benot
Natividad Calvo Romero
Fritz Diekmann
Alicia Mendiluce
Constantino Fernández Rivera
Roberto Gallego
Carlos Jiménez
Paloma L. Martin‐Moreno
Ernesto Fernández Tagarro
Cándido Díaz
Basilio Martín Urcuyo
Francisco Manuel González Roncero
author_facet Amado Andrés
Sara Jiménez
Maria José Aladrén Regidor
Francesc Moreso
Marta Crespo
Nuria Serra Cabañas
Gonzalo Gómez
Verónica López
Maria del Carmen Díaz Corte
Pilar Fraile‐Gómez
Inmaculada Lorenzo
Juan Carlos Ruiz San Millán
Laura Cañas
Alberto Rodríguez Benot
Natividad Calvo Romero
Fritz Diekmann
Alicia Mendiluce
Constantino Fernández Rivera
Roberto Gallego
Carlos Jiménez
Paloma L. Martin‐Moreno
Ernesto Fernández Tagarro
Cándido Díaz
Basilio Martín Urcuyo
Francisco Manuel González Roncero
Amado Andrés
Sara Jiménez
Maria José Aladrén Regidor
Francesc Moreso
Marta Crespo
Nuria Serra Cabañas
Gonzalo Gómez
Verónica López
Maria del Carmen Díaz Corte
Pilar Fraile‐Gómez
Inmaculada Lorenzo
Juan Carlos Ruiz San Millán
Laura Cañas
Alberto Rodríguez Benot
Natividad Calvo Romero
Fritz Diekmann
Alicia Mendiluce
Constantino Fernández Rivera
Roberto Gallego
Carlos Jiménez
Paloma L. Martin‐Moreno
Ernesto Fernández Tagarro
Cándido Díaz
Basilio Martín Urcuyo
Francisco Manuel González Roncero
collection Wiley Open Access
contents Clinical Outcomes and Quality of Life in Older De Novo Kidney Transplant Recipients Under Once‐Daily Tacrolimus Formulations: The BITACORA Study Amado Andrés Sara Jiménez Maria José Aladrén Regidor Francesc Moreso Marta Crespo Nuria Serra Cabañas Gonzalo Gómez Verónica López Maria del Carmen Díaz Corte Pilar Fraile‐Gómez Inmaculada Lorenzo Juan Carlos Ruiz San Millán Laura Cañas Alberto Rodríguez Benot Natividad Calvo Romero Fritz Diekmann Alicia Mendiluce Constantino Fernández Rivera Roberto Gallego Carlos Jiménez Paloma L. Martin‐Moreno Ernesto Fernández Tagarro Cándido Díaz Basilio Martín Urcuyo Francisco Manuel González Roncero Clinical Transplantation ABSTRACT Introduction Although advanced age is no longer a contraindication for renal transplantation, real‐world data on elderly transplant recipients remain limited. Methods This multicenter, prospective study enrolled de novo kidney transplant recipients aged 60 years or older receiving once‐daily tacrolimus immunosuppression, following recovery of renal function and referral to the transplant clinic. The primary objective was to describe clinical characteristics and post‐transplant outcomes over a 12‐month follow‐up. Secondary objectives included assessing changes in quality of life and the relationship between biopsy‐proven acute rejection (BPAR) and tacrolimus levels. Results Of 280 evaluable patients, 239 completed the 12‐month follow‐up (mean recipient age: 69.8 years; mean donor age: 69.1 years) and 41 (14.6%) terminated due to graft loss (13, 31.7%), tacrolimus termination (12, 29.3%), death (10, 24.4%), loss to follow‐up (3, 7.3%), other (2, 4.9%), and temporary tacrolimus interruption (1, 2.4%). BPAR occurred in 8.2% of patients who showed significantly higher tacrolimus levels vs those without BPAR over the follow‐up (9.8 ng/mL vs. 8.9 ng/mL; p = 0.01). Opportunistic infections were reported in 78.3% patients with BPAR vs 58.8% without BPAR ( p = 0.07). Quality of life improved across different domains of the Kidney Transplant Questionnaire and the ESRD‐SCL. Conclusion This study monitored clinical outcomes during the first year post‐transplant in older de novo kidney transplant recipients receiving grafts from older donors and under a once‐daily tacrolimus‐based immunosuppressive regimen. The incidence of BPAR, graft loss, and mortality was low, and patients generally experienced an improvement in quality of life, indicating an effective and safe procedure in this population. 10.1111/ctr.70501 http://creativecommons.org/licenses/by-nc/4.0/
doi_str_mv 10.1111/ctr.70501
format Artículo Open Access
id wiley_oa_10_1111_ctr_70501
institution Wiley Open Access
license_str_mv http://creativecommons.org/licenses/by-nc/4.0/
publishDate 2026
publisher Wiley
record_format wiley_oa
spellingShingle Clinical Outcomes and Quality of Life in Older De Novo Kidney Transplant Recipients Under Once‐Daily Tacrolimus Formulations: The BITACORA Study
Amado Andrés
Sara Jiménez
Maria José Aladrén Regidor
Francesc Moreso
Marta Crespo
Nuria Serra Cabañas
Gonzalo Gómez
Verónica López
Maria del Carmen Díaz Corte
Pilar Fraile‐Gómez
Inmaculada Lorenzo
Juan Carlos Ruiz San Millán
Laura Cañas
Alberto Rodríguez Benot
Natividad Calvo Romero
Fritz Diekmann
Alicia Mendiluce
Constantino Fernández Rivera
Roberto Gallego
Carlos Jiménez
Paloma L. Martin‐Moreno
Ernesto Fernández Tagarro
Cándido Díaz
Basilio Martín Urcuyo
Francisco Manuel González Roncero
Clinical Transplantation
Clinical Outcomes and Quality of Life in Older De Novo Kidney Transplant Recipients Under Once‐Daily Tacrolimus Formulations: The BITACORA Study Amado Andrés Sara Jiménez Maria José Aladrén Regidor Francesc Moreso Marta Crespo Nuria Serra Cabañas Gonzalo Gómez Verónica López Maria del Carmen Díaz Corte Pilar Fraile‐Gómez Inmaculada Lorenzo Juan Carlos Ruiz San Millán Laura Cañas Alberto Rodríguez Benot Natividad Calvo Romero Fritz Diekmann Alicia Mendiluce Constantino Fernández Rivera Roberto Gallego Carlos Jiménez Paloma L. Martin‐Moreno Ernesto Fernández Tagarro Cándido Díaz Basilio Martín Urcuyo Francisco Manuel González Roncero Clinical Transplantation ABSTRACT Introduction Although advanced age is no longer a contraindication for renal transplantation, real‐world data on elderly transplant recipients remain limited. Methods This multicenter, prospective study enrolled de novo kidney transplant recipients aged 60 years or older receiving once‐daily tacrolimus immunosuppression, following recovery of renal function and referral to the transplant clinic. The primary objective was to describe clinical characteristics and post‐transplant outcomes over a 12‐month follow‐up. Secondary objectives included assessing changes in quality of life and the relationship between biopsy‐proven acute rejection (BPAR) and tacrolimus levels. Results Of 280 evaluable patients, 239 completed the 12‐month follow‐up (mean recipient age: 69.8 years; mean donor age: 69.1 years) and 41 (14.6%) terminated due to graft loss (13, 31.7%), tacrolimus termination (12, 29.3%), death (10, 24.4%), loss to follow‐up (3, 7.3%), other (2, 4.9%), and temporary tacrolimus interruption (1, 2.4%). BPAR occurred in 8.2% of patients who showed significantly higher tacrolimus levels vs those without BPAR over the follow‐up (9.8 ng/mL vs. 8.9 ng/mL; p = 0.01). Opportunistic infections were reported in 78.3% patients with BPAR vs 58.8% without BPAR ( p = 0.07). Quality of life improved across different domains of the Kidney Transplant Questionnaire and the ESRD‐SCL. Conclusion This study monitored clinical outcomes during the first year post‐transplant in older de novo kidney transplant recipients receiving grafts from older donors and under a once‐daily tacrolimus‐based immunosuppressive regimen. The incidence of BPAR, graft loss, and mortality was low, and patients generally experienced an improvement in quality of life, indicating an effective and safe procedure in this population. 10.1111/ctr.70501 http://creativecommons.org/licenses/by-nc/4.0/
title Clinical Outcomes and Quality of Life in Older De Novo Kidney Transplant Recipients Under Once‐Daily Tacrolimus Formulations: The BITACORA Study
topic Clinical Transplantation
url https://onlinelibrary.wiley.com/doi/10.1111/ctr.70501